ES2196530T3 - Compuestos de ruptura para inactivar patogenos. - Google Patents

Compuestos de ruptura para inactivar patogenos.

Info

Publication number
ES2196530T3
ES2196530T3 ES98901776T ES98901776T ES2196530T3 ES 2196530 T3 ES2196530 T3 ES 2196530T3 ES 98901776 T ES98901776 T ES 98901776T ES 98901776 T ES98901776 T ES 98901776T ES 2196530 T3 ES2196530 T3 ES 2196530T3
Authority
ES
Spain
Prior art keywords
compounds
methods
materials
nucleic acid
inactivate pathogens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98901776T
Other languages
English (en)
Inventor
David Cook
John Merritt
Aileen Nerio
Henry Rapoport
Adonis Stassinopoulos
Susan Wollowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerus Corp
Original Assignee
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Corp filed Critical Cerus Corp
Application granted granted Critical
Publication of ES2196530T3 publication Critical patent/ES2196530T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0209—Multiple bag systems for separating or storing blood components
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B01J20/28033—Membrane, sheet, cloth, pad, lamellar or mat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/64—Acridine or hydrogenated acridine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un compuesto para inactivar los patógenos en la sangre o en productos sanguíneos, que comprende: un resto enlazante de ácido nucleico; un resto efector, capaz de formar un enlace covalente con el ácido nucleico; y un conector de ruptura unido covalentemente al resto enlazante de ácido nucleico y al resto efector: en el que el conector de ruptura se degrada hasta que deja de unir covalentemente al resto enlazante de ácido nucleico y al resto efector y en el que la hidrólisis del conector de ruptura al ser sometido a incubación con la sangre o con el producto sanguíneo tiene lugar a la vez que la reacción del efector con el ácido nucleico, pero a una velocidad suficientemente lenta para permitir la inactivación de patógenos en la sangre o en el producto sanguíneo, en unas condiciones tales que no hagan que la sangre o el producto sanguíneo sean inadecuados para el propósito al que se destinan.
ES98901776T 1997-01-06 1998-01-06 Compuestos de ruptura para inactivar patogenos. Expired - Lifetime ES2196530T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77988597A 1997-01-06 1997-01-06
US77983097A 1997-01-07 1997-01-07
US4369697P 1997-04-15 1997-04-15

Publications (1)

Publication Number Publication Date
ES2196530T3 true ES2196530T3 (es) 2003-12-16

Family

ID=27366374

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98901776T Expired - Lifetime ES2196530T3 (es) 1997-01-06 1998-01-06 Compuestos de ruptura para inactivar patogenos.

Country Status (10)

Country Link
EP (1) EP1021414B1 (es)
JP (2) JP4551502B2 (es)
CN (2) CN101676268B (es)
AT (1) ATE243198T1 (es)
AU (1) AU744089C (es)
CA (1) CA2276532C (es)
DE (1) DE69815703T2 (es)
ES (1) ES2196530T3 (es)
HK (2) HK1026702A1 (es)
WO (1) WO1998030545A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1021414B1 (en) * 1997-01-06 2003-06-18 Cerus Corporation Frangible compounds for pathogen inactivation
DE69826521T2 (de) * 1998-01-06 2005-09-29 Cerus Corp., Concord Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien
AU4435399A (en) 1998-06-11 1999-12-30 Cerus Corporation Inhibiting proliferation of arterial smooth muscle cells
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
US20020042043A1 (en) * 2000-05-31 2002-04-11 Adonis Stassinopoulos Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
DE10051628B4 (de) * 2000-10-18 2007-06-06 Fresenius Hemocare Beteiligungs Gmbh Einzelsträngiges Oligonukleotid und dessen Verwendung
AU2001298078A1 (en) * 2000-12-21 2003-09-02 Cerus Corporation Methods for inactivation of pathogens in biological materials
JP4545151B2 (ja) 2003-02-06 2010-09-15 シーラス コーポレイション 非食細胞中への侵入について減弱化されているリステリア、そのリステリアを含むワクチン、およびそれらの使用法
KR101173871B1 (ko) * 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
EP1838355B1 (en) 2004-10-29 2013-08-14 Cerus Corporation Improved quenching methods for red blood cell inactivation process
BRPI0911176B8 (pt) 2008-04-09 2021-05-25 Cerus Corp método de tratar uma composição de célula vermelha sanguínea, composição de célula vermelha sanguínea, e método de reduzir a desidratação em uma composição de célula vermelha sanguínea
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
CN104788373A (zh) * 2015-05-06 2015-07-22 武汉大学 化合物s-303盐酸盐的合成方法
WO2016210374A1 (en) 2015-06-26 2016-12-29 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
CN104991033A (zh) * 2015-08-05 2015-10-21 上海海虹实业(集团)巢湖今辰药业有限公司 一种采用一测多评法测定川芎挥发油成分的方法
CA3003097A1 (en) 2015-10-23 2017-04-27 Cerus Corporation Plasma compositions and methods of use thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
JP2019533641A (ja) 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態およびその使用
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP2020503512A (ja) * 2016-12-23 2020-01-30 シーラス コーポレイション 化合物結合基材を使用して、試験およびスクリーニングするためのシステムおよび方法
BR112019018273A2 (pt) 2017-03-03 2020-07-14 Cerus Corporation kits e métodos para preparação de composições de plaquetas inativadas por patógenos
BR112020013178A2 (pt) 2017-12-29 2020-12-01 Cerus Corporation sistemas e métodos para tratamento de fluidos biológicos
EP3986499A2 (en) 2019-06-22 2022-04-27 Cerus Corporation Biological fluid treatment systems
EP3991179A1 (en) 2019-06-28 2022-05-04 Cerus Corporation System and methods for implementing a biological fluid treatment device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020090A1 (en) * 1993-03-17 1994-09-15 Steritech, Inc. Decontaminating clinical samples
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
DE4444045C2 (de) * 1994-12-10 1997-04-17 Behringwerke Ag Verfahren zur Inaktivierung von Viren mit Hilfe von Acridin oder Acridinderivaten
EP0773716A4 (en) * 1995-06-07 1999-08-04 Cerus Corp TREATMENT OF RED BLOOD CELL SOLUTIONS WITH ANTIVRAL ACTIVE SUBSTANCES
EP1021414B1 (en) * 1997-01-06 2003-06-18 Cerus Corporation Frangible compounds for pathogen inactivation

Also Published As

Publication number Publication date
CN101676268B (zh) 2013-09-25
DE69815703D1 (de) 2003-07-24
EP1021414A1 (en) 2000-07-26
HK1026702A1 (en) 2000-12-22
CN101676268A (zh) 2010-03-24
WO1998030545A1 (en) 1998-07-16
AU5821798A (en) 1998-08-03
JP2010095527A (ja) 2010-04-30
AU744089C (en) 2003-07-31
ATE243198T1 (de) 2003-07-15
AU744089B2 (en) 2002-02-14
DE69815703T2 (de) 2004-06-03
EP1021414B1 (en) 2003-06-18
CN1248245B (zh) 2012-07-04
CN1248245A (zh) 2000-03-22
HK1188441A1 (en) 2014-05-02
CA2276532A1 (en) 1998-07-16
JP4551502B2 (ja) 2010-09-29
JP5244083B2 (ja) 2013-07-24
JP2001508449A (ja) 2001-06-26
CA2276532C (en) 2008-06-17

Similar Documents

Publication Publication Date Title
ES2196530T3 (es) Compuestos de ruptura para inactivar patogenos.
ATE287210T1 (de) Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffen
ES2147752T3 (es) Descontaminacion de plaquetas con 8-metoxipsoraleno.
DK0653911T3 (da) Fremgangsmåder til inaktivering af bakterier i blodpræparater med 8-methoxypsoralen
DE60135498D1 (de) Produktion von ganzen Antikörpern in prokaryontischen Zellen
DE69031389D1 (de) Schnelle, vielseitige und einfache methode zur expression von genen in eukaryotischen zellen
AU9058091A (en) Preparation of nucleic acid samples
FI962799A (fi) Nukleiinihappoja sisältävä valmiste, sen valmistus ja käyttö
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
WO2005025615A3 (en) FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
BRPI0414979A (pt) preparação sólida
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
ATE253117T1 (de) Adenovirus e4 proteine für induktion von zelltod
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
ATE233093T1 (de) Arzneimittel zur vermeidung und umkehrung der atherosklerose bei säugetieren
GB9723824D0 (en) Cytostatic agents
UA32241A (uk) Спосіб лікування запалювальних процесів у експериментальних тварин
ATE46360T1 (de) Plasminogenaktivator fuer menschliches gewebe, diesen aktivator enthaltende pharmazeutische zusammensetzungen, verfahren zur herstellung des aktivators sowie dna und transformierte zellzwischenprodukte hierfuer.
UA23145A (uk) Спосіб визhачеhhя активhості бромелаїhу
WO2003063763A3 (en) Complement mediated assays for in vivo and in vitro methods
WO2001011358A3 (en) Use of colored metal binding proteins
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози